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Introduction
Vaccines based on cancer cells modified ex vivo to express a range of different immunomodulatory genes have generated antitumour immunity in preclinical models (reviewed in Refs 1 and 2), leading to clinical trials of antimetastatic cancer cell vaccines. [3] [4] [5] [6] In contrast to tumours of histological types often associated with relatively high levels of intrinsic immunogenicity, such as melanoma, 7 colorectal cancer is often considered to be less immunogenic and, therefore, less amenable to vaccination approaches. However, since deaths due to colorectal cancer in the USA in 1996 were expected to exceed 54 000, whereas melanoma was expected to kill 7 300 people, it would be of great value if effective immunotherapies for this disease could be developed.
Despite the perception that colorectal cancer is poorly immunogenic, there is extensive evidence that immune targets exist and that both cell mediated and humoral responses can be stimulated in vivo. For example, clinical trials using an anti-idiotype antibody to mimic a colorectal surface antigen have been encouraging. 8 In addition, several potential antigens have been identified in colorectal cancer, including mutated p21ras, mucin, keratin-like molecules and carcinoembryonic antigen. [9] [10] [11] [12] [13] Similarly, tumour infiltrating lymphocyte (TIL) populations have been identified in colorectal cancers, and their presence has been associated with increased patient survival.
14 Tumour-specific CTL that use limited TcR variable regions have also been isolated, suggesting clonal expansion in response to specific antigenic determinants. 15 ␥␦ T cells have also been identified which, following stimulation with IL-2 and IL-7, have specific CTL activity towards epithelial-derived tumours in a nonMHC restricted manner. 16 Furthermore, it has been reported that ␥␦ T cells can also recognise heat shock proteins (hsp), 17 molecules which are constitutively expressed by some colorectal cancers (S Todryk, unpublished) and which may provide alternative pathways by which immunogenic peptides can be presented to the immune system. In addition, several studies have demonstrated that it is possible to isolate cytotoxic cells specific for colorectal tumour cells in vitro. 18, 19 Simultaneously, however, it is also clear that colorectal tumour cells can also develop effective mechanisms to escape immune clearance, including loss of expression of MHC class I molecules and production of immunosuppressive factors, such as transforming growth factor (TGF-)␤, 20 IL-10, 21 leukaemia inhibitory factor, prosta-glandins 22, 23 as well as Fas ligand which can induce apoptosis in tumour infiltrating T cells bearing the Fas receptor. 24 In human disease, functional suppression of T cells also appears to coincide with alterations in the TcR signal transduction mechanism, 25 but these defects may be reversible by cytokines such as IL-2. Production of any or all of these factors by tumour cells in situ may, in part, explain why colorectal tumours tend to develop and persist, despite the presence of TIL.
Hence, although there are barriers to effective immune recognition of colorectal tumour cells, some or all of these might be overcome in vivo by using appropriate immune manipulation. 26 In addition, this disease potentially lends itself to immunotherapy since subsets of patients exist in which, following surgery, occult metastases exist which might be small enough to be contained by an appropriately activated immune response.
Data from mouse models of colorectal cancer have been particularly encouraging for the development of effective immunotherapy. For example, transfection of the murine colorectal line CT26 with the GM-CSF gene leads to potent protection against parental tumour cell challenge. 27, 28 Protection correlates with the production in vivo of protective CTL which recognise an epitope derived from an endogenous retroviral envelope emv-1. 29 However, it is not yet clear whether the expression of emv-1 has occurred as a result of long-term culture of the cell line in the absence of any in vivo immunoselective pressure. 29 Alternatively, it may represent a true tumour antigen, the expression of which genuinely reflects the transformation process. If the former is true, the immunogenic value of the envelope as a model for colorectal tumour antigens may be minimal. Other studies have also shown that colorectal cell immunogenicity can be enhanced by gene transfer, although the selection of the optimal gene is heavily model dependent. 2 Any cell-associated vaccine must display the antigens likely to be expressed on metastatic cells as fully as possible, both quantitatively and qualitatively. The close matching of the antigenic repertoire of the vaccine with that of metastases could be achieved in one of three ways. Ideally, the development of targeted, high efficiency vectors for direct in vivo gene delivery 30, 31 would ensure that tumour cells growing in orthotopic environments could be transduced while displaying the complete array of tumour antigens in the context of the encoded immunomodulatory gene. 32, 33 Second, it might be possible to use a mixture of allogeneic cells which express a wide variety of antigens known to be expressed on diverse colorectal tumours. 34 Finally, if vaccines are to be prepared ex vivo, they should be out of the patient for the minumum amount of time to reduce antigenic drift and transduction with the appropriate gene must be rapid and efficient. The majority of ex vivo vaccines have so far been prepared using retroviral transduction to generate stably expressing cell populations with integrated vectors. [3] [4] [5] [6] However, even without the need for selection of infected cells, 35 the requirement of retroviral vectors for target cell division still requires medium-term culture of tumour cells following surgery. In contrast, higher efficiency vector systems might remove the need for integration into the target cells because high levels of transient expression should be sufficient to activate the immune system in vivo. 36, 37 The primary objectives of this study were: (1) to compare the efficacy of three separate classes of immunomodulatory genes to induce antitumour immune responses when expressed in murine colorectal cells; (2) to demonstrate that colorectal tumours can reproducibly be explanted and established in short-term culture; and (3) to develop a rapid transduction protocol by which these fresh tumour explants can be engineered to express high levels of biological response modifiers within 1-2 weeks of surgery, so that the modified cells can be used in clinical vaccination studies.
Results
Construction of gene-modified murine colorectal cell lines We compared the biological activity of three different classes of immunomodulatory genes in the CMT93 murine colorectal cell line. These comprised cytokines (IL-2 or GM-CSF), a costimulatory molecule (B7.1) or a suicide gene (HSVtk). CMT93 cell lines expressing these genes were isolated as described in Materials and methods. To control for the effects of expression of the selectable marker genes alone, CMT93 puro and CMT93 neo were also generated by infection of parental cells with the pBabe Puro and pBabe Neo 'empty' vectors.
Effect of transgene expression on primary tumorigenicity of colorectal tumour cells
To determine the immunomodulatory effects of these genes on tumour growth in vivo, animals were injected s.c. with 2 × 10 6 parental or gene modified cells. The mean diameter of the tumours in each group was used as a measure of the rate of tumour growth (Figure 1 ). Transduced genes had one of three effects. The first category (neo, HSVtk in the absence of GCV treatment and GM-CSF) had no significant inhibitory effect on the rate of tumour growth. In fact, in two experiments, GM-CSFtransduced cells consistently grew slightly more aggressively than the parental cells (Figure 1a) . The second category (IL-2, puro) significantly retarded, but did not abrogate growth of the tumour compared with parental cells (Figure 1b) . The third category of genes, which included HSVtk in combination with the prodrug ganciclovir and the co-stimulatory molecule B7.1, was effective in completely eliminating the tumorigenicity of CMT93 cells (Figure 1c) . However, in a few cases (two of nine mice), in animals in which CMT93tk tumours had initially been eradicated by treatment with GCV, tumour recurrence was observed at least 60 days following tumour inoculation. When tumours were recovered from these animals, although both retained the HSVtk gene by PCR analysis, neither showed continued expression of the gene by rtPCR (data not shown). Parallel studies in our laboratory have also shown that IL-12 and B7.2 fall into the third class of genes and abrogate tumorigenicity of CMT93 cells. 64 Effect of transgene expression on immunogenicity of colorectal tumour cells To assess which gene-modified vaccine will best protect against metastatic disease, animals in which the primary tumour had either never grown (CMT93 B7.1 or CMT93tk) or had been resected no fewer than 14 days previously, were rechallenged with 2 × 10 6 parental CMT93 cells on the opposite flank. Growth of the challenge tumour was monitored and the number of tumourfree animals by day 60 following rechallenge was assessed ( Figure 2 ). Typically, naive animals, animals in which the primary tumour was unmodified, or which expressed the neo selectable marker gene alone, all developed progressively growing tumours by day 60 after challenge ( Figure 2 ). The puro selectable marker gene conferred a low level of protection (less than 20% of animals protected). Killing of the primary tumour by HSVtk in combination with GCV treatment, enhanced the immunogenicity of the CMT93 cells by similar amounts to B7.1 (between 40 and 50% of the animals being protected). In contrast, expression of IL-2, or GM-CSF protected over 60% of animals from tumour development on rechallenge. Of these two, GM-CSF was consistently more effective at inducing protection.
Explanted, irradiated murine tumours infected with Ad-GM-CSF generate systemic protection similar to GM-CSF-expressing long-term cell lines Because the corresponding human clinical protocol will require tumour explant at surgery, transduction with the appropriate vector, cell irradiation and reinjection of cytokine-producing irradiated tumour cells as a vaccine, we performed this experiment with the CMT93 model. Explanted CMT93 tumours were infected with the AD-GM-CSF vector in vitro and then irradiated. Irradiated, GM-CSF producing cultures were then injected into mice as a vaccine followed by rechallenge with parental CMT93 cells to mimic the human clinical situation. Figure 3 demonstrates that, whereas mice injected with mock-infected CMT93 parental cells in this protocol gave no superior protection compared with naive animals, treatment with irradiated, Ad-GM-CSF-infected CMT93 cells gave significant protection against a rechallenge with viable parental cells (P Ͻ 0.01 stratified log-rank test). Moreover, the protection seen with this vaccine preparation was long lasting (since animals were rechallenged over 1 month following vaccination) and was directly comparable to that generated with the long-term culture cell lines as described in Figure 2 (typically about 60% of treated animals were protected by days 40-60 following challenge).
Rapid establishment of colorectal tumour cell explants in culture
On the basis of these data, we sought to demonstrate that fresh human colorectal tumour cells could be transduced with appropriate therapeutic genes in a way that would be therapeutically useful. Fresh colorectal tumours were recovered from the operating theatre and established in culture overnight according to the protocol described in Jaffee et al 35 (see Materials and methods). Typically between 10 6 and 10 7 cells could be recovered and established in short-term culture by 24-72 h following surgery. From a total of 17 consecutive tumours supplied from theatre, 14 were established in short-term culture while the remaining four were lost to contamination or failed to yield any appreciable cell numbers. From these shortterm cultures we have been able to passage five lines which could be frozen and thawed and maintained for at least 10 passages in culture.
To confirm that significant numbers of tumour cells were recovered, as opposed to contaminating fibroblasts, we used immunofluorescence with the antibody LP34 which recognises epithelial cell-specific cytokeratins. Although the proportion varied between different tumour samples, we were routinely able to detect positive staining cells from the recovered cell populations (Figure 4) , confirming the presence of colorectal tumour cells in the short-term cultures.
Gene transduction of fresh human colorectal cancer cells without long-term culture Twenty-four to 72 hours following surgery, approximately 10 5 cells of the recovered cell populations were infected with the retroviral vector (MFG-␤-Gal, 10 6 c.f.u.) or adenoviral vector stocks (AD-␤-Gal, 250 MOI). Fortyeight hours later, cells were stained for expression of the ␤-Gal reporter gene to assess the efficiency of infection. From a series of 14 fresh human tumour samples, the mean efficiency of infection with Ad-␤-Gal was 52% compared with 19% with the MFG-␤-Gal retroviral vector (Table 1A) . With the exception of a single culture of colorectal cells, which was infected at a level of 70% by the MFG vector, transduction efficiency with adenoviral stocks was consistently superior to the use of the retroviral vector (Table 1A and Figure 5 ).
Adenoviral transduction of fresh human colorectal cancer cells leads to expression of therapeutic levels of cytokine or cytotoxic genes Next we investigated whether transduction with adenoviral vectors could achieve potentially therapeutic levels of gene expression in the freshly resected colorectal cells. We used two different adenoviral vectors to infect fresh tumour explants (250 MOI). Ad-IL-2 expresses the IL-2 gene from the CMV promoter. Ad-tk-GM-CSF expresses both the HSVtk and the GM-CSF genes from the CMV promoter using an internal ribosome entry site to allow coordinate expression of both genes from a single promoter. 65 Tumour samples could be reproducibly infected with the Ad-IL-2 vector and generated similar levels of IL-2 production (maximum of 3-9 ng IL-2/10 5 cells/48 h after infection) across a series of seven different tumours ( Figure 6 ). Similar results were obtained with the Ad-tk-GM-CSF vector (maximum levels of 10-20 ng GM-CSF/10 5 cells/48 h after infection). In parallel, tumours were also infected with the retroviral vector pBabe Neo IL-2. We were unable to detect any IL-2 expression from cultures infected in this way 48 h following infection ( Figure 6 ), even though IL-2 could readily be detected in CMT93 cells infected in parallel in vitro (data not shown).
Kinetics of adenovirus-mediated cytokine expression in tumour explants
To assess the longevity of gene expression following adenoviral infection, tumours 10-14 were also stained for ␤-Gal expression 7 days following infection. Whereas in general, the proportion of stained cells decreased in adenovirus-infected cultures, it remained largely constant in cultures infected with MFG-␤-Gal (except for tumour 11) (Table 1B) . At 48 h after adenoviral infection, cultures showed high levels of infection and intense blue staining compared with lower levels of infection with the corresponding retroviral vector (Figure 5a ). Seven days and 12 days after infection, both levels and intensity of staining of adenoviral infection decreased (Figure 5b and c) . In contrast, clonal expansion of retrovirus-infected cells led to a stable, or increasing proportion of blue staining cells. An example of an expanding clone following retroviral infection is shown in Figure 5c .
In addition, we followed the kinetics of cytokine expression from Ad-infected explants. Initially, we compared the levels of expression of GM-CSF from Ad-tk-GM-CSF-infected fresh tumour cultures with three similarly infected human colorectal cell lines which have been A series of 14 consecutive fresh tumour explants were infected with either adenoviral vector stocks (AD-␤-Gal, 250 MOI) or the retroviral vector (MFG-␤-Gal, 10 6 c.f.u.) 24-72 h following surgery. Forty-eight hours later, cells were stained for expression of the ␤-Gal reporter gene to assess the efficiency of infection.
established long term in culture. Cytokine production over consecutive 48 h periods peaked between 2 and 4 days following infection in freshly isolated cultures (T4 and T8, Figure 7a ). Interestingly, within this period of time, levels of GM-CSF production were significantly higher from the fresh cultures ( than from the established cell lines SW620, HT29 or LoVo (2-3 ng/10 5 cells/48 h). Moreover, these infected human explants, which would form the basis of the colon cancer vaccines to be used in clinical trials, produced GM-CSF at the same, or higher levels than those which we have already demonstrated to be efficacious in the corresponding murine model (Figure 3) .
Infection with the Ad-␤Gal vector showed that this effect correlated with lower infectability of the established lines by the Ad vectors (data not shown) for reasons which are currently being investigated. Similarly, levels of secreted IL-2 in any 48 h period peaked from infected cells between 2 and 6 days following viral infection (Figure 7b ) showing that these kinetics are not dependent upon the cytokine being used. In each shortterm tumour culture tested, production of the cytokine subsequently fell off by day 10 following infection, presumably reflecting the dilution of the vector as the cells divided in vitro (Figure 7 ).
Discussion
Since previous experience suggests that immunotherapy is only likely to be effective under conditions of minimal residual disease, 26, 27, 38, 39 colorectal cancer potentially offers an excellent opportunity for immunotherapy to make a significant impact on patient treatment. 40 This is because there exists a distinct subset of patients in which, following surgery, occult metastases exist which would be small enough to be contained by an appropriately activated immune response. However, as with all novel treatments in the adjuvant setting, it will take large numbers of patients and long periods of time to demonstrate the value of such a treatment.
The three primary objectives of this study were: (1) to investigate which class of immunomodulatory gene, when transduced into a murine colorectal tumour cell
Figure 7 Cytokine production from tumour explants following transduction with adenoviral vectors. (a) GM-CSF: Tumour explants T4 and T8 as well as established human colorectal cell lines SW620, HT29 and LoVo, (5 × 10 4 cells) were infected with Ad-tk-GM-CSF (250 MOI) stock. Medium was harvested at the time intervals shown and assayed for GM-CSF by ELISA. Fresh medium was replaced on to the cultures and these were subsequently assayed for GM-CSF production at 48 h intervals. (b) IL-2: Tumour explants T2, T3 and T8 (5 × 10 4 cells) were infected with Ad-IL-2 (250 MOI) stock and 48 h later medium was removed and assayed for IL-2 by ELISA. Fresh medium was replaced on to the cultures and these were subsequently assayed for IL-2 production at 48 h intervals.
line, could best confer antitumour immunity in a prophylactic model; (2) to demonstrate that fresh tumour explants of human colorectal tumours could be established in short-term culture long enough for gene transduction to be performed; and (3) to compare the ability of retroviral and adenoviral vectors rapidly to generate high levels of gene expression in the explanted 'vaccine' cells before a significant period of time in culture could distort their antigenic profile. These studies provide the rationale and practical basis for implementation of an ex vivo vaccination protocol for colorectal cancer. They also provide encouragement that adenoviral vectors could be used as an efficient system for the direct delivery of therapeutic genes to colorectal tumours in situ.
We studied three different types of immunomodulatory genes in the murine CMT93 model, including cytokines, 2,3 costimulatory genes 41 and a suicide gene. 42 The effects of expression of the marker genes used to generate the cell lines were also assessed since bacterial marker genes can alter the growth profile of some cell lines. 43 Ideally, the optimal therapeutic gene would have potent antitumour effects on both tumorigenicity and immunogenicity, and could be used for direct delivery to colorectal tumours growing in situ. As such it would lead to death of the tumour cells themselves (without the need for surgery) and would generate potent antitumour immunity to other, systemic, nontransduced metastatic deposits. However, our results demonstrated a rank order of efficacy against primary tumour growth of HSVtk[GCV], B7.1 Ͼ puro, IL-2 ϾGM-CSF, neo ( Figure 1 ) and a rank order of efficacy in inducing antitumour immunity of GM-CSF, IL-2, Ͼ B7.1, HSVtk[GCV] puro, neo ( Figure 2 ). Parallel studies in our laboratory have also shown that, although expression of B7.2 appears to be slightly superior to B7.1, both IL-12 and B7.2 induce levels of protection (typically between 50 and 60% protected animals) below that produced by GM-CSF in the same protocol. 64 Therefore, from those genes tested, GM-CSF, or possibly IL-2, would be the optimal choice for generation of a single gene-modified colorectal cell vaccine in the setting of ex vivo cell modification. These results are consistent with other studies in which both GM-CSF 3,27,44,45 or IL-2 2,38,46 have been shown to be potent enhancers of tumour cell immunogenicity in other models. We cannot exclude the possibility that, had different levels of expression been obtained from any of the cytokine secreting lines used in this study, the relative efficacies might have been different, since dosage effects are important in determining immunogenicity. 47, 48 With respect to the other genes studied here, we currently do not favour the use of either of the B7 costimulatory genes in a single gene modification protocol because the interactions of B7 molecules with T cell stimulatory (CD28) and T cell inhibitory ligands (CTLA-4) is complex and the outcome of vaccination with B7 expressing cells is difficult to predict. 49, 50 In addition, although the immunising effect of in vivo cell killing with HSVtk/GCV was clearly detectable in this model, it was less effective than in other cell lines. 33, 51, 52 We are currently studying the basis of these effects and how the mechanisms of cell killing by the HSVtk/GCV system affect in vivo immunogenicity in different tumour models. 66 As the next stage of our analysis, we are currently generating doubly gene-modified CMT93 lines, co-expressing two cytokines together, a cytokine and a costimulatory molecule, or a suicide gene and a cytokine. As well as enhancing the vaccine efficacy, 26 we hope that such combinations may simultaneously lead to vectors for direct in vivo delivery able to kill both the primary tumour cells as well as distant metastases. In addition, although we used a prophylactic vaccination model here, we are investigating a model in which CMT93 tumours can be seeded as liver metastases and treated by the vaccine cells. Such a model system will mimic more closely the situation in which such vaccines will eventually be used clinically.
Although it would eventually be preferable to develop in vivo delivery protocols, current vector technology 30, 31 suggests that ex vivo tumour cell modification of colorectal cells is likely to be the best first step in development of vaccines for this disease. There are several persuasive arguments, both practical and immunological, for the development of vaccines derived from allogeneic cultures of colorectal cells, including ease of preparation and administration to patients and the predicted immunostimulatory effects of allogeneic cross-reactivities. 34, 53 However, if autologous vaccines could be rapidly and efficiently prepared they should display the antigens most relevant to each individual patient. However, to be immunologically relevant they must retain a representative profile of tumour antigens following any genetic manipulations which are required ex vivo. In this respect, it is important first to establish appreciable numbers of tumour cells rapidly in culture. We have shown here that fresh human tumour explants can reproducibly be established in short-term cultures direct from surgery. Once experienced in the procedures, we were successful in a large proportion of cases in recovering cells from these explants. These cultures consisted of tumour cells mixed with fibroblasts, although the relative proportions differed between samples. However, other groups have demonstrated that cytokine gene-transduced fibroblasts are effective when used to deliver cytokines to high local concentrations in the presence of tumour antigens displayed on admixed tumour cells. 47, 54 Therefore, transduction of tumour cells and fibroblasts alike in the explanted cultures would still be expected to be beneficial.
Following explanting, a large proportion of cells must be transduced before they significantly alter their antigenic/immunological profile once released from in vivo immunoselective pressures. This would argue against the use of delivery vehicles which require longterm culture and/or in vitro selection for effective transduction. Previous ex vivo modification experiments have used retroviral vectors 3,5 or DNA complexes 48 to transfer cytokine genes to tumour populations. Since C-type retroviral vectors require cell division for infection, these protocols usually require extended periods of cell culture, even without the need for selection. 35 Therefore, we used adenoviral vectors expressing the ␤-Gal gene to demonstrate that high proportions of the short-term cultures of colorectal cells could be transduced within a short period (Ͻ2 weeks from original surgery). On the basis of our results in the animal model system, we also used adenoviral vectors expressing the IL-2 or GM-CSF genes to show that these cells can be engineered to express levels of cytokine which previous animal studies would predict to be therapeutic. 5 Adenovirus-mediated gene delivery was reproducibly, and significantly, more efficient, over the time-frame of importance for vaccination, than retroviral transduction using the MFG-␤-Gal retroviral vector, which is the vector used in human trials of GM-CSFmodified vaccine cells.
3 The IL-2 adenoviral vector produced high levels of IL-2 reproducibly over the tumours tested, whereas a retroviral IL-2 vector did not yield detectable cytokine 48 h following exposure of the cells to virus.
One possible drawback of the adenoviral system is that 876 levels of ␤-Gal and IL-2 expression were seen to fall off quite rapidly after the peak at 2-6 days following infection. Levels of retroviral expression of ␤-Gal, although much lower, remained largely stable in the infected populations, or increased slightly with time, as infected cells divided and passed the transgene to their progeny. However, chronic expression of the transgene would not be required because immune stimulation should occur within days of return of the cytokine-expressing cells to the patient. In addition, the vaccine cells will be irradiated before in vivo return, thereby necessarily limiting the expression of the gene. We are currently investigating the effects of cell irradiation on the levels and longevity of transgene expression from adenovirusinfected tumour cells. In addition, we and others are actively investigating other vector systems which may be superior in terms of titre, and rapidity, of transgene expression in human colorectal tumour explants. 36, 37 Our results are also encouraging for the future development of direct in vivo gene delivery systems for which two principal scenarios can be envisaged. In the first, high efficiency, tumour cell-targeted vectors could be delivered systemically to target organs where metastases are located (such as the liver). However, the twin requirements of high efficiency and rigid targeting still makes this approach a relatively distant possibility. 30 The alternative is the injection of vectors directly into an established tumour deposit, which may be either the primary tumour before resection or an accessible metastasis.
In summary, we have confirmed that it is possible to induce antitumour immunity in a murine colorectal model and that GM-CSF is the most effective single gene modification of those tested so far. Moreover, we have developed a rapid adenovirus-mediated procedure by which fresh explants of human colorectal tumours can be engineered to express high, therapeutic levels of such immunostimulatory genes ready for reintroduction into patients as few as 10 days following surgery. Future improvements will include the use of double gene-modified vaccine cells, investigation of alternative high titre, rapid transducing vectors and, eventually, direct in vivo gene transfer methods. Combination of the animal model data with the ex vivo modification protocol suggests that vaccination of colorectal patients of the appropriate stage will be possible and effective.
Materials and methods
Cell culture CMT93 is a murine colorectal tumour line derived from a C57/BL mouse. 55 The human colorectal tumour cell lines SW620, LoVo and HT29 were obtained from the ATCC. All cell lines were monitored routinely and found to be free of Mycoplasma infection. The lines were grown in Dulbecco's modified Eagle's minimal essential medium supplemented with 10% (v/v) fetal calf serum and 4 nm l-glutamine. For cell killing in vitro, this medium was supplemented with ganciclovir (Cymevene, Roche, Welwyn Garden City, UK) to a final concentration of 5 g/ml or 10 g/ml. Cells were selected in 1.25 g/ml puromycin (Sigma, Poole, UK) for the transfer of the puro (puromycin-resistance) gene or in 1 mg/ml G418 (GIBCO, Paisley, UK) for transfer of the neo (neomycinresistance) gene.
Construction of expression plasmids, retroviral and adenoviral vectors
Subcloning was performed using standard recombinant DNA techniques. 56 The retroviral vectors pBabePuro mB7.1, pBabeneo-IL-2 and pBabeneo-GM-CSF were constructed from the pBabe vectors 57 and have been described previously.
49, 58 The HSVtk gene was taken from the plasmid Tyr-tk 59 and cloned into the expression plasmid PCR3 (Invitrogen, Leek, The Netherlands) in which a CMV promoter directs expression of the gene.
The adenoviral vectors Ad-␤-Gal and Ad-IL-2 were constructed by cloning the ␤-Gal or IL-2 genes into the adenoviral shuttle vector pXCJL.1 and virus was generated by in vivo recombination in 293 cells following cotransfection with the adenoviral backbone plasmid pJM17. 60 The adenoviral vector Ad-tk-GM-CSF was constructed as described elsewhere. 58 Exact restriction maps and details of all constructs are available on request.
Generation of recombinant virus stocks
The production of retrovirus stocks and infection of target cells has been described previously. 61 Briefly, retroviral vector plasmid DNA was transfected into the AM12 amphotropic packaging line. 62 After incubation in selection medium for 3 weeks surviving colonies were pooled. Viral supernatant was then harvested and used to infect target cells in the presence of 4 g/ml polybrene. All viral stocks were shown to be free of helper virus as described elsewhere. 
DNA transfection
Adherent cells (10 6 ) were transfected with 10 g of plasmid DNA by calcium phosphate coprecipitation using the Profection method (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Generation of gene-modified cell lines
The CMT93 IL-2, CMT93 GM-CSF, CMT93 B7.1, CMT93 puro or CMT93 neo cell lines were generated following retrovirus-mediated infection of the parental cell line with the appropriate viral stocks. Individual clones were selected in puromycin or G418 containing medium, screened for expression of the transgene and those with highest levels of expression were selected for further study.
The CMT93tk line was generated by cotransfection of the HSVtk gene into CMT93 cells along with pSV40 puro as a selectable marker.
Detection of cytokine production from cell lines and selection of CMT93 lines for study Cells of transfected or infected cell lines were seeded in normal medium. Forty-eight hours later, supernatant was 877 harvested and filtered (0.2 m Nalgene filter) and the cells were trypsinised and counted. The supernatant was assayed for interleukin-2 or GM-CSF by ELISA using antibody pairs obtained from Pharmingen (Cambridge BioScience, Cambridge, UK). CMT93 clones selected for study in this work produced cytokines as follows: CMT93-IL-2: 8 ng/10 6 cells/48 h; CMT93-GM-CSF: 1.4 ng/10 6 cells/48 h. The parental CMT93 cell line did not produce any detectable cytokines.
The CMT93tk clone which was most sensitive to treatment with ganciclovir, was selected and used in these studies.
The CMT93.B7.1 line selected for use was chosen on the basis of highest level of B7 expression by FACS analysis as described in Ref. 49 .
Establishment of primary cultures from human colorectal tumour explants
Freshly resected tumour samples were washed twice in cold PBS containing 50 g/ml of gentamicin (Boehringer Mannheim, Lewes, E Sussex, UK) and washed once in RPMI medium containing gentamicin at 50 g/ml and fungizone (Sigma) at 2.5 g/ml. The samples were then minced in a Petri dish into fragments of about 1-5 mm in size using scalpels. From 1 g of tumour sample, 9 ml of dissociated tumour in digestion medium (RPMI medium, gentamicin 10 mg/ml, Pen/Strep), were digested with 1 mg/ml Collagenase-Dispase (Boehringer Mannheim) and 0.1 mg/ml DNaseI (Boehringer Mannheim) for 30-60 min with vigorous shaking at 37°C. The medium, which now contained single cells, was then taken and kept on ice. A new digestion was set up with the solid fragments left in the tube. This procedure was repeated at least once. A final digestion was performed which consisted of digestion medium containing 0.25% trypsin and 1 mm EDTA. All the collected medium was pooled and spun down at 150 g for 5 min. The pellet was resuspended in RPMI 10% FCS containing 0.2 units/ml of human insulin (Sigma) and 40 g/ml of bovine pituitary extract (Sigma), plus antibiotics. Cells were plated in sixwell plates. Cells were passaged routinely at 70-80% confluency and split one in three.
␤-Galactosidase histochemical assay
Medium from transduced cells was aspirated off and wells were washed three times with complete PBS. Cells were fixed with 4% formaldehyde in PBS for at least 10 min at 4°C. Fixed cells were then washed twice with complete PBS and filtered X-gal stain (100 mm sodium phosphate pH 7.3(77 mm Na 2 HPO 4 , 23 mm NaH 2 PO 4 ), 1.3 mm MgCl 2 , 3 mm K 3 Fe(CN) 6 , 3 mm K 4 Fe(CN) 6 and 1 mg/ml X-gal) was added. Cells were incubated at 37°C overnight. The percentage of blue cells was determined following light microscope visualisation.
Indirect immunofluorescence
Tumour cell explants (1 × 10 4 ) were plated on 10 mm diameter glass coverslips in 48-well plates. After 24 h incubation, cells were washed twice with 0.1% BSA in PBS (wash buffer) and fixed for 10 min at room temperature with a solution of 1:1 acetone:methanol. Following three washes over 5 min, the wells were incubated for 10 min at room temperature with 3% BSA/PBS to prevent nonspecific binding. Cells were incubated for 45 min at room temperature with 100 ml of the first layer antibody.
After three washes, the cells were incubated for 30 min at room temperature with 100 ml of the FITC (DAKO, Glostrup Denmark, diluted 1:80 in 3% BSA in PBS) second layer. During this incubation the plates were wrapped in silver foil. The cells were washed three times with wash buffer, mounted on to glass microscope slides in Citifluor (Citifluor UKC, Canterbury, UK). Excess mountant was blotted with 3 MM Whatman paper and the coverslips sealed with clear nail-varnish. Coverslips were examined on a fluorescent photo-microscope (Axioplan Zeiss Microscope, Munich, Germany).
In vivo injection of tumour cells C57BL/6 mice were obtained from colonies bred at the Imperial Cancer Research Fund. Mice were age and sexmatched for individual experiments. To establish subcutaneous tumours, 2 × 10 6 CMT93 cells were injected s.c. (100 l) into the flank region. Animals were examined daily until the tumour became palpable, whereafter the diameter, in two dimensions, was measured thrice weekly using calipers. Where appropriate, animals received daily injections i.p. of either ganciclovir (70 mg/kg for treatment) or saline (control) in 100 l volumes for 5 consecutive days, starting at day 5 following tumour seeding unless otherwise stated. Animals were killed, or had tumours surgically excised (see below), when tumour size was approximately 1.0 × 1.0 cm in two perpendicular directions.
Tumour rechallenge
Tumours which were established from the primary inoculation were excised when the size was approximately 1.0 × 1.0 cm. Mice were then rechallenged with s.c. injection of 2 × 10 6 parental CMT93 cells on the opposite flank. Mice which had rejected the initial inoculation of tumour cells were also rechallenged. All groups of mice in any one individual experiment were rechallenged on the same occasion using the same preparation of cells. The animals were rechallenged 14 days following the most recent surgical excision that had been performed on any mouse in the cohort. A naive group of mice was also injected with these cells at the same time. Animals were examined daily until the tumour became palpable, whereafter the diameter, in two dimensions, was measured thrice weekly using calipers. Animals were killed when tumour size was approximately 1.0 × 1.0 cm in two perpendicular directions.
Statistical analyses
Data from the animal studies were analysed by the logrank test. 63 
